CAMLG anticorps (N-Term)
Aperçu rapide pour CAMLG anticorps (N-Term) (ABIN630925)
Antigène
Voir toutes CAMLG AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- CAMLG antibody was raised against the N terminal of CAMLG
-
Purification
- Affinity purified
-
Immunogène
- CAMLG antibody was raised using the N terminal of CAMLG corresponding to a region with amino acids LLMNSEQRINRIMGFHRPGSGAEEESQTKSKQQDSDKLNSLSVPSVSKRV
-
-
-
-
Indications d'application
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
CAMLG Blocking Peptide, (ABIN5612597), is also available for use as a blocking control in assays to test for specificity of this CAMLG antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CAMLG antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- CAMLG (Calcium Modulating Ligand (CAMLG))
-
Autre désignation
- CAMLG
-
Sujet
- The immunosuppressant drug cyclosporin A blocks a calcium-dependent signal from the T-cell receptor (TCR) that normally leads to T-cell activation. When bound to cyclophilin B, cyclosporin A binds and inactivates the key signaling intermediate calcineurin. CAMLG functions similarly to cyclosporin A, binding to cyclophilin B and acting downstream of the TCR and upstream of calcineurin by causing an influx of calcium. This integral membrane protein appears to be a new participant in the calcium signal transduction pathway, implicating cyclophilin B in calcium signaling, even in the absence of cyclosporin.
-
Poids moléculaire
- 33 kDa (MW of target protein)
-
Pathways
- EGFR Signaling Pathway
Antigène
-